Compare FLNA & HYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNA | HYFT |
|---|---|---|
| Founded | 1998 | 1983 |
| Country | United States | United States |
| Employees | 20 | 102 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 71.9M |
| IPO Year | N/A | N/A |
| Metric | FLNA | HYFT |
|---|---|---|
| Price | $1.25 | $1.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 346.0K | ★ 569.5K |
| Earning Date | 05-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.16 | $0.99 |
| 52 Week High | $2.03 | $3.00 |
| Indicator | FLNA | HYFT |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 50.41 |
| Support Level | $1.16 | $1.56 |
| Resistance Level | $1.80 | $1.96 |
| Average True Range (ATR) | 0.10 | 0.18 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 4.41 | 7.02 |
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.